Spark Therapeutics (ONCE) Rating Reiterated by Cantor Fitzgerald

Spark Therapeutics (NASDAQ:ONCE)‘s stock had its “overweight” rating restated by Cantor Fitzgerald in a report released on Thursday. They presently have a $80.00 price objective on the biotechnology company’s stock, down from their prior price objective of $103.00. Cantor Fitzgerald’s target price points to a potential upside of 84.50% from the company’s current price.

Other equities analysts also recently issued reports about the stock. Raymond James restated a “buy” rating on shares of Spark Therapeutics in a research note on Friday, September 21st. William Blair restated a “buy” rating on shares of Spark Therapeutics in a research note on Friday, September 21st. Zacks Investment Research upgraded shares of Spark Therapeutics from a “hold” rating to a “buy” rating and set a $54.00 price objective for the company in a research note on Wednesday, October 10th. Guggenheim assumed coverage on shares of Spark Therapeutics in a research note on Tuesday, October 9th. They issued a “buy” rating and a $70.00 target price for the company. Finally, Mizuho cut their target price on shares of Spark Therapeutics to $62.00 and set a “buy” rating for the company in a research note on Wednesday, November 7th. One analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $65.20.

Shares of NASDAQ ONCE opened at $43.36 on Thursday. The firm has a market capitalization of $1.67 billion, a P/E ratio of -5.68 and a beta of 1.98. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.71 and a quick ratio of 10.36. Spark Therapeutics has a 1-year low of $34.53 and a 1-year high of $96.59.

Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($1.26) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.04) by ($0.22). Spark Therapeutics had a negative return on equity of 14.18% and a negative net margin of 127.82%. The business had revenue of $10.70 million for the quarter, compared to analyst estimates of $27.44 million. During the same quarter in the prior year, the company earned ($1.90) earnings per share. The company’s quarterly revenue was up 463.2% on a year-over-year basis. Sell-side analysts expect that Spark Therapeutics will post -1.53 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in ONCE. Bank of New York Mellon Corp raised its stake in Spark Therapeutics by 4.9% during the second quarter. Bank of New York Mellon Corp now owns 141,367 shares of the biotechnology company’s stock worth $11,700,000 after buying an additional 6,613 shares during the last quarter. Schwab Charles Investment Management Inc. increased its stake in Spark Therapeutics by 9.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 165,264 shares of the biotechnology company’s stock valued at $13,678,000 after purchasing an additional 13,894 shares in the last quarter. BlackRock Inc. increased its stake in Spark Therapeutics by 8.7% in the second quarter. BlackRock Inc. now owns 2,869,232 shares of the biotechnology company’s stock valued at $237,459,000 after purchasing an additional 229,786 shares in the last quarter. FMR LLC increased its stake in Spark Therapeutics by 2.6% in the second quarter. FMR LLC now owns 5,536,564 shares of the biotechnology company’s stock valued at $458,206,000 after purchasing an additional 142,428 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new stake in Spark Therapeutics in the second quarter valued at $4,635,000.

About Spark Therapeutics

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

Recommended Story: Leveraged Buyout (LBO)

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply